Donanemab clinical trials
Also written LY3002813 and Kisunla.
How each study uses donanemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the donanemab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Jul 2024 · KISUNLA · BLA 761248 (FDA, Drugs@FDA)
- European Union
- 24 Sept 2025 · Kisunla · EMEA/H/C/006024 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 3
Eli Lilly and Company (14) · Paul S. Aisen (1) · Michael Rafii, MD, PhD (1) · Banner Health (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test donanemab, phase 3 first.
- Nov 2027A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Phase 3 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses donanemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RecruitingPhase 2Eli Lilly and CompanyNCT07589595Written as Donanemab
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).RecruitingPhase 3Eli Lilly and CompanyNCT07602582Written as Donanemab
- Alzheimer's Tau Platform: Regimen A - AADvac1Enrolling by invitationPhase 2Paul S. AisenNCT07167966Written as Donanemab
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's DiseaseNot yet recruitingPhase 4Eli Lilly and CompanyNCT07838155Written as Donanemab
- A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseRecruitingPhase 2/3Banner HealthNCT06996730Written as Donanemab
- Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT07571161Written as Donanemab
- Amyloid Lowering for Alzheimer's in Down's With Donanemab InvestigationNot yet recruitingPhase 4Michael Rafii, MD, PhDNCT06911944Written as Donanemab
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Active, not recruitingPhase 3Eli Lilly and CompanyNCT05508789Written as Donanemab
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Active, not recruitingPhase 3Eli Lilly and CompanyNCT04437511Written as Donanemab
- A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)CompletedPhase 2Eli Lilly and CompanyNCT03367403Written as Donanemab
- A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT05026866Written as Donanemab
- A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)CompletedPhase 2Eli Lilly and CompanyNCT04640077Written as donanemab
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)CompletedPhase 3Eli Lilly and CompanyNCT05108922Written as Donanemab
- A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or ADCompletedPhase 1Eli Lilly and CompanyNCT02624778Written as LY3002813
- A Study of LY3002813 in Participants With Alzheimer's DiseaseCompletedPhase 1Eli Lilly and CompanyNCT01837641Written as LY3002813-IV
- A Study of Donanemab (LY3002813) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05567159Written as Donanemab
- A Study of Donanemab (LY3002813) in Healthy Chinese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05533411Written as Donanemab
Given beside what is tested · 1 — donanemab is usual care or a partner of the new treatment
Codes
What other systems call donanemab · ClinicalTrials.gg INT002035
- MeSH (NLM) C000729112donanemabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1ADB65P1KKDONANEMABConfirmed FDA, NLM
- NCI Thesaurus C166484DonanemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729112 | donanemab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1ADB65P1KK | DONANEMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C166484 | Donanemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.